Agomelatine, a novel intriguing antidepressant option enhancing neuroplasticity: A critical review
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: The treatment of major affective disorders, commonly associated with high disability and elevated social costs may be still considered unsatisfactory. Among all antidepressant drugs, predominantly acting through monoaminergic mechanisms, agomelatine is of particular interest due to another alternative mechanism of action. Targeting melatonergic receptors, agomelatine play a crucial role in synchronizing circadian rhythms, known to be altered in depressed subjects. METHODS: A critical review of the literature focusing on efficacy, safety and tolerability of agomelatine in major affective disorders was performed. Additionally, we focused on the potential of agomelatine in enhancing neuroplasticity mechanisms and promote neurogenesis. A total of 136 articles from peer-reviewed journals were identified, of which 50 were assessed for eligibility and 21 were included. RESULTS: Agomelatine, a melatonergic analogue drug acting as MT1/MT2 agonist and 5-HT2C antagonist, has been reported to be effective as antidepressant drug. Studies confirmed not only clinical efficacy but also safety and tolerability of agomelatine. Also, it enhances neuroplasticity mechanisms and adult neurogenesis in brain areas such as hippocampus and prefrontal cortex. CONCLUSIONS: Agomelatine actually represents an intriguing option in the treatment of affective disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stress, Depression, and Neuroplasticity: A Convergence of Mechanisms
Pittenger, C., & Duman, R. S. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301574 · Cited by 1,795 · cited 2×
“Also, agomelatine may promote neurogenesis and enhance levels of brain-derived neurotrophic factor in the hippocampus (Manji et al. 2003; Pittenger and Duman 2008; Reznikov et al. 2009; Soumier et al. 2009).”
BackgroundNew approaches to antidepressant drug discovery: beyond monoamines
Berton, O., & Nestler, E. J. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1846 · Cited by 1,589
Anderson, I. M. (2000) · Journal of Affective Disorders · doi:10.1016/s0165-0327(99)00092-0 · Cited by 940 · cited 1×
“…does not induce 5-HT2A stimulation having a more favourable adverse-effect profi le compared with the common SSRIs, particularly about sexual functioning, weight gain, gastrointestinal disturbances and discontinuation symptoms (Anderson 2000; Oli é and Kasper 2007; Kasper and Hamon 2009).”
BackgroundVEGF links hippocampal activity with neurogenesis, learning and memory
Cao, L., Jiao, X., Zuzga, D. S., Liu, Y., Fong, D. M., Young, D., & During, M. J. (2004) · Nature Genetics · doi:10.1038/ng1395 · Cited by 850
Report by the ACNP Task Force on Response and Remission in Major Depressive Disorder
Rush, A. J., Kraemer, H. C., Sackeim, H. A., Fava, M., Trivedi, M. H., Frank, E., Ninan, P. T., Thase, M. E., Gelenberg, A. J., Kupfer, D. J., et al. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301131 · Cited by 707 · cited 1×
“The goal of antidepressant treatment in major depressive disorders is to reach full remission of depressive symptoms as well as return to premorbid functioning (Rush et al. 2006).”
BackgroundRole of neurotrophic factors in depression
CASTREN, E., VOIKAR, V, & RANTAMAKI, T. (2007) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.08.009 · Cited by 667 · cited 1×
“…antidepressants may increase neurotrophin signalling promoting neuronal and synaptic remodelling as well as the formation of new hippocampal neurons both in the hippocampus and prefrontal cortex (Duman 2004; McEwen and Chattarji 2004; Castren et al. 2007; Sairanen et al. 2007; Bessa et al. 2009).”
BackgroundBessa, J. M., Ferreira, D., Melo, I., Marques, F., Cerqueira, J. J., Palha, J. A., Almeida, O. F. X., & Sousa, N. (2009) · Molecular Psychiatry · doi:10.1038/mp.2008.119 · Cited by 598 · cited 1×
“…antidepressants may increase neurotrophin signalling promoting neuronal and synaptic remodelling as well as the formation of new hippocampal neurons both in the hippocampus and prefrontal cortex (Duman 2004; McEwen and Chattarji 2004; Castren et al. 2007; Sairanen et al. 2007; Bessa et al. 2009).”
BackgroundCastrén, E. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1629 · Cited by 563
Role of Neurotrophic Factors in the Etiology and Treatment of Mood Disorders
Duman, R. S. (2004) · NeuroMolecular Medicine · doi:10.1385/nmm:5:1:011 · Cited by 537
Goodwin, G. M., Emsley, R., Rembry, S., Rouillon, F., & the Agomelatine Study Group (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04548 · Cited by 340
Cited by
Is there an association between diet and depression in children and adolescents? A systematic review
Khalid, S., Williams, C. M., & Reynolds, S. A. (2016) · British Journal of Nutrition · doi:10.1017/s0007114516004359 · Cited by 276
Barnes, N. M., Ahern, G. P., Becamel, C., Bockaert, J., Camilleri, M., Chaumont-Dubel, S., Claeysen, S., Cunningham, K. A., Fone, K. C., Gershon, M., et al. (2021) · Pharmacological Reviews · doi:10.1124/pr.118.015552 · Cited by 263
Non-pharmacological treatment of depression: a systematic review and evidence map
Farah, W. H., Alsawas, M., Mainou, M., Alahdab, F., Farah, M. H., Ahmed, A. T., Mohamed, E. A., Almasri, J., Gionfriddo, M. R., Castaneda-Guarderas, A., et al. (2016) · Evidence Based Medicine · doi:10.1136/ebmed-2016-110522 · Cited by 141
“Concerns about antidepressants’ efficacy and tolerability in patients with major depressive disorder have led to investigating newer agents with alternative mechanism of action, such as agents that enhance neuroplasticity and neurogenesis.(11) These concerns have also led to increased interest in non-pharmacological t…”
BackgroundGruzdev, S. K., Yakovlev, A. A., Druzhkova, T. A., Guekht, A. B., & Gulyaeva, N. V. (2019) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-019-00684-6 · Cited by 75
Shi, Y., Song, R., Wang, Z., Zhang, H., Zhu, J., Yue, Y., Zhao, Y., & Zhang, Z. (2021) · eBioMedicine · doi:10.1016/j.ebiom.2021.103337 · Cited by 65
“[5] Pompili M, Serafini G, Innamorati M, et al.”
Background
Metadata
- Authors
- Pompili, M., Serafini, G., Innamorati, M., Venturini, P., Fusar-Poli, P., Sher, L., Amore, M., & Girardi, P.
- Venue
- The World Journal of Biological Psychiatry
- Publisher
- Informa UK Limited
- Published
- 2013-03-26
- Volume
- 14
- Issue
- 6
- Pages
- 412-431
- ISSN
- 1562-2975 (ISSN-L)
- 1814-1412
- OpenAlex
- W2067573473
- Cited by
- 78
- References
- 17
- FWCI
- 5.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Agomelatine, a novel intriguing antidepressant option enhancing neuroplasticity: A critical review. https://app.cochat.ai/papers/10.3109/15622975.2013.765593
- The paper
- Pompili, M., Serafini, G., Innamorati, M., Venturini, P., Fusar-Poli, P., Sher, L., Amore, M., & Girardi, P. (2013). Agomelatine, a novel intriguing antidepressant option enhancing neuroplasticity: A critical review. The World Journal of Biological Psychiatry. https://doi.org/10.3109/15622975.2013.765593
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.